Anondita Medicare IPO is set to open on August 22, 2025, and will close on August 26, 2025. This IPO is a Book Built Issue, through which the company aims to raise around ₹69.50 crores. The issue comprises a fresh issue of ₹69.50 crores, while the Offer for Sale (OFS) details are yet to be announced. Each share has a face value of ₹10.
The IPO price band is fixed at ₹137 to ₹145 per share, with a retail quota of 35%, QIB quota of 50%, and HNI quota of 15%. The listing will be on NSE SME on September 1, 2025, and the allotment date is scheduled for August 28, 2025.
Financial Performance: The company reported a revenue of ₹77.13 crores in 2025, up from ₹46.56 crores in 2024. Its profit surged to ₹16.42 crores in 2025 compared to ₹3.84 crores in 2024. Considering these strong financials, investors are advised to consider this IPO for long-term investment.
Anondita Medicare IPO Date & Price Band Details
| Category | Details |
|---|---|
| IPO Open Date: | August 22, 2025 |
| IPO Close Date: | August 26, 2025 |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹137 to ₹145 Per Share |
| Issue Size: | Approx ₹69.50 Crores |
| Fresh Issue: | Approx ₹69.50 Crores |
| Lot Size: | 1,000 Shares |
| Issue Type: | Book Built Issue |
| IPO Listing: | NSE SME |
| Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
| Anchor Investors List: | Click Here |
Anondita Medicare IPO Market Lot
The Anondita Medicare IPO has a minimum market lot of 2,000 shares, which corresponds to an application amount of ₹2,90,000.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 2,000 | ₹2,90,000 |
| Retail Maximum | 2 | 2,000 | ₹2,90,000 |
| S-HNI Minimum | 3 | 3,000 | ₹4,35,000 |
| B-HNI Minimum | 7 | 7,000 | ₹10,15,000 |
Anondita Medicare IPO Allotment & Listing Dates
The Anondita Medicare IPO will open on August 22, 2025, and close on August 26, 2025. The allotment date is scheduled for August 28, 2025, and the IPO will be listed on the NSE SME on September 1, 2025.
| Type | Date |
|---|---|
| IPO Open Date: | August 22, 2025 |
| IPO Close Date: | August 26, 2025 |
| Basis of Allotment: | August 28, 2025 |
| Refunds: | August 29, 2025 |
| Credit to Demat Account: | August 29, 2025 |
| IPO Listing Date: | September 1, 2025 |
Anondita Medicare IPO: Promoters
The promoters of Anondita Medicare are Mr. Anupam Ghosh, Mrs. Sonia Ghosh, and Mr. Reshant Ghosh.
Anondita Medicare IPO Company Financial Report
Anondita Medicare reported a revenue of ₹77.13 crores in 2025, up from ₹46.56 crores in 2024. The profit surged to ₹16.42 crores in 2025, compared to ₹3.84 crores in 2024, reflecting strong financial growth.
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
|---|---|---|---|---|
| 2023 | ₹36.14 | ₹35.67 | ₹0.35 | ₹37.80 |
| 2024 | ₹46.56 | ₹41.40 | ₹3.84 | ₹42.92 |
| 2025 | ₹77.13 | ₹55.18 | ₹16.42 | ₹78.27 |
Anondita Medicare IPO Valuation – FY2025
| KPI | Values |
|---|---|
| ROE: | 41.71% |
| ROCE: | 37.42% |
| EBITDA Margin: | 33.32% |
| PAT Margin: | 21.32% |
| Debt to equity ratio: | 0.97 |
| Earning Per Share (EPS): | ₹9.60 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 38.10% |
| Net Asset Value (NAV): | ₹21.32 |
Anondita Medicare IPO Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Cupid Limited | 1.52 | 110.38 | 11.96 | 12.75 | 40.93 Cr. |
Objects of the Issue – Anondita Medicare IPO
- Funding capital expenditure requirements for the purchase of equipment and machinery
- Funding the working capital requirement
- Unidentified acquisition and general corporate purposes
Anondita Medicare Company Overview, Strengths, and Risks
Anondita Medicare Ltd. is an Indian manufacturer of healthcare and personal care products, with a primary focus on male condoms. The company, which was established in 2024 as a public limited company, is part of the larger Anondita Group, which has a history in the healthcare business dating back to 1999. Its flagship product is the male condom, sold under the brand name “COBRA.”
The company has a significant installed production capacity of nearly 562 million condoms per year at its facility in Noida, Uttar Pradesh. Anondita Medicare operates in both domestic and international markets, exporting its products to regions such as Southeast Asia, Africa, and the Middle East. A key part of its business model is supplying products to government health programs, NGOs, and other health organizations, in addition to its retail brand presence. The company also produces other items like surgical gloves and is involved in the research and development of female condoms.
Strengths
- Large-Scale Production Capacity: The company boasts a substantial annual production capacity of 562 million condoms, which positions it as a significant player in the Indian market.
- Established Brand Presence: The “COBRA” brand is recognized, particularly in North India, providing a strong foundation for its retail business.
- Strategic Partnerships: Anondita Medicare has strong relationships with government health programs, NGOs, and institutional buyers, which provides a consistent stream of demand and revenue. This also aligns the company with public health initiatives, which can be a stable business segment.
- Growing Financial Performance: The company has demonstrated strong financial growth, with significant increases in both total income and profit after tax (PAT) in recent fiscal years.
- Experienced Management: The company is led by promoters with decades of industry experience, which is a crucial asset, especially for a newly incorporated public entity.
- Diverse Product Portfolio: While condoms are the primary product, the company has ventured into surgical gloves and is developing female condoms, offering a degree of product diversification.
Risks
- Reliance on a Niche Product: A significant portion of the company’s revenue is derived from the sale of condoms. This heavy concentration makes it vulnerable to shifts in market demand, consumer preferences, or regulatory changes specific to this product category.
- Dependence on Key Customers: A large percentage of the company’s revenue is generated from a limited number of top customers, particularly government tenders. The loss of a major customer or a significant reduction in their orders could have a severe impact on the company’s financial performance.
- Geographical Concentration: The business has a high dependency on a few key states in India, such as Delhi, Uttar Pradesh, and Haryana. This geographical concentration can expose the company to regional economic downturns or policy changes.
- Intense Competition: The condom market is highly competitive, with both large domestic and international players vying for market share. This can put pressure on pricing and profit margins.
- Regulatory and Policy Risks: As a manufacturer of medical devices and healthcare products, the company is subject to strict and evolving regulations. Any changes in government policies related to healthcare, family planning, or manufacturing standards could affect its operations.
- Raw Material Price Volatility: Fluctuations in the cost of raw materials, such as latex, could directly impact the company’s profitability.
- SME IPO-Specific Risks: As a newly listed SME, the stock may face risks such as lower liquidity compared to mainboard listings, making it difficult for investors to buy or sell shares. The valuation may also be considered high by some analysts based on recent financial figures, which could be a concern for potential investors.
Anondita Medicare IPO Review
- Canara Bank
- DRChoksey FinServ
- Emkay Global
- Hem Securities
- IDBI Capital
- Marwadi Shares
- Nirmal Bang
- SBICAP Securities
- Sharekhan
- SMC Global
- Sushil Finance
- Swastika Investmart
- Ventura Securities
- Geojit
- Reliance Securities
- Capital Market
- BP Wealth
- ICICIdirect
- Choice Broking
Anondita Medicare IPO Registrar
Maashitla Securities Pvt.Ltd.
Phone: +91-11-45121795-96
Email: ipo@maashitla.com
Website: https://maashitla.com/allotment-status/public-issues
Anondita Medicare IPO Lead Managers aka Merchant Bankers
- Narnolia Financial Services Ltd.
Anondita Medicare Company Address
Anondita Medicare Ltd.
Flat No.704 Narmada Block,
N6, Sec-D,
Pkt-6 Vasant Kunj,
New Delhi, New Delhi, 110070
Phone: 0120-4520300
Email: info@anonditamedicare.com
Website: https://anonditamedicare.com
FAQs about Anondita Medicare IPO
The IPO price band has been set at ₹137 to ₹145 per share.
For retail investors, the minimum and maximum application is 2 lots, which consists of 2,000 shares, with an application amount of ₹2,90,000.
The total issue size is approximately ₹69.50 crores, which is a fresh issue of shares.
The IPO will open for subscription on August 22, 2025, and will close on August 26, 2025.
The company plans to use the net proceeds from the fresh issue for capital expenditure to purchase equipment and machinery, fund its working capital requirements, and for general corporate purposes.
The shares of Anondita Medicare will be listed on the NSE SME platform.
The promoters of Anondita Medicare are Mr. Anupam Ghosh, Mrs. Sonia Ghosh, and Mr. Reshant Ghosh.
The basis of allotment is tentatively scheduled for August 28, 2025.
The company has shown strong financial growth, with revenue increasing from ₹46.56 crores in 2024 to ₹77.13 crores in 2025 and a profit after tax (PAT) surge from ₹3.84 crores to ₹16.42 crores in the same period.
Anondita Medicare is primarily a manufacturer of male condoms, with its flagship brand being “COBRA.” The company also produces surgical gloves and is involved in the development of female condoms.
